{
    "patientInformation": {
        "name": "Sarah Miller",
        "mrn": "MC-001001",
        "dateOfBirth": "1962-03-15",
        "age": 63,
        "sex": "Female"
    },
    "presentingComplaint": "Severe fatigue, jaundice, epigastric pain, confusion.",
    "medicalHistory": {
        "conditions": [
            "Rheumatoid arthritis",
            "Essential hypertension",
            "Mild chronic kidney disease"
        ],
        "allergies": [
            "Penicillin (rash)"
        ],
        "socialHistory": "Drinks ~1-2 beers/day (7-14 units/week). Smoked ~1 pack/day (35 pack-year history), quit in 2017. Retired carpenter."
    },
    "medications": {
        "chronicPriorToEvent": [
            "Methotrexate 20 mg weekly",
            "Folic Acid 5 mg weekly",
            "Lisinopril 10 mg daily"
        ],
        "initiatedAtAcuteEvent": "Trimethoprim-Sulfamethoxazole 800/160 mg BID (June 15, 2025 - June 25, 2025)"
    },
    "keyLaboratoryFindings": {
        "encounterDate": "2025-06-21",
        "results": [
            {
                "test": "ALT",
                "value": "1650 U/L",
                "flag": "H",
                "reference": "7.0 - 56",
                "note": "↑↑↑"
            },
            {
                "test": "AST",
                "value": "2100 U/L",
                "flag": "H",
                "reference": "8.0 - 40",
                "note": "↑↑↑"
            },
            {
                "test": "Alkaline Phosphatase",
                "value": "350 U/L",
                "flag": "H",
                "reference": "40 - 150",
                "note": "↑↑"
            },
            {
                "test": "Total Bilirubin",
                "value": "12.5 mg/dL",
                "flag": "H",
                "reference": "0.2 - 1.2",
                "note": "↑↑↑"
            },
            {
                "test": "INR",
                "value": "1",
                "flag": "",
                "reference": "0.8 - 1.2",
                "note": "Normal"
            }
        ]
    },
    "diagnosis": {
        "main": "Drug-Induced Liver Injury (DILI)",
        "causality": "Acute hepatocellular injury most likely induced by Trimethoprim-Sulfamethoxazole, with potential potentiation or contribution from chronic Methotrexate therapy.",
        "mechanism": "Trimethoprim-Sulfamethoxazole can cause idiosyncratic DILI. It can also interact with Methotrexate, increasing its serum levels and potentiating hepatotoxicity. The acute onset following TMP-SMX initiation strongly suggests it as the primary culprit."
    },
    "differentialDiagnosisTracker": {
        "diagnoses": [
            {
                "name": "Drug-Induced Liver Injury (DILI)",
                "status": "PRIMARY",
                "notes": "Strong temporal association with TMP-SMX initiation, characteristic lab pattern (hepatocellular), and presence of jaundice/confusion."
            },
            {
                "name": "Methotrexate Toxicity",
                "status": "INVESTIGATE",
                "notes": "Chronic MTX use, known hepatotoxin. May be contributing or potentiated by TMP-SMX. Need to check MTX levels."
            },
            {
                "name": "Acute Viral Hepatitis",
                "status": "PENDING",
                "notes": "Pending serologies."
            }
        ],
        "ruledOut": []
    },
    "easlAssessment": {
        "overallImpression": "Sarah Miller, a 63-year-old female, presents with severe hepatocellular DILI, most likely triggered by trimethoprim-sulfamethoxazole (TMP-SMX) initiated 6 days prior to presentation, in the context of chronic methotrexate use. She presents with jaundice, confusion, elevated transaminases (ALT 1650 U/L), and elevated bilirubin (12.5 mg/dL), consistent with significant liver injury.",
        "diliDiagnosticCriteriaMet": [
            {
                "criterion": "ALT ≥ 5 × ULN",
                "status": "MET",
                "details": "ALT 1650 U/L. Assuming a typical ULN of 56 U/L, this is approximately 29.5x ULN."
            },
            {
                "criterion": "ALT ≥ 3 × ULN with bilirubin ≥ 2 × ULN",
                "status": "MET",
                "details": "ALT 1650 U/L (approx. 29.5x ULN) and Total Bilirubin 12.5 mg/dL (assuming ULN of 1.2 mg/dL, this is approx. 10.4x ULN). Both thresholds are met."
            },
            {
                "criterion": "Alkaline Phosphatase (ALP) ≥ 2 × ULN (cholestatic pattern)",
                "status": "NOT MET",
                "details": "ALP 350 U/L. Assuming a typical ULN of 150 U/L, this is approx. 2.3x ULN. However, the ALT elevation is far more pronounced, indicating a hepatocellular pattern rather than cholestatic."
            },
            {
                "criterion": "R-ratio (ALT/ALP) / (ULN ALT/ULN ALP)",
                "status": "MET",
                "details": "ALT 1650 U/L, ALP 350 U/L. Assuming ULNs of ALT 56 U/L and ALP 150 U/L, the R-ratio is (1650/350) / (56/150) = 4.71 / 0.373 ≈ 12.6. An R-ratio > 5 indicates a hepatocellular pattern."
            }
        ],
        "causativeAgentAssessment": [
            {
                "agent": "Trimethoprim-Sulfamethoxazole",
                "role": "HIGHLY SUSPECTED PRIMARY TRIGGER",
                "rationale": "Temporal association: initiated 6 days prior to symptom onset and presentation. Known hepatotoxin with idiosyncratic DILI potential. Interaction with methotrexate is also a concern."
            },
            {
                "agent": "Methotrexate",
                "role": "SIGNIFICANT CO-FACTOR",
                "rationale": "Long-term use in patient with DILI risk factors (age, potential alcohol use, mild CKD). Methotrexate itself is a known cause of DILI and can interact with TMP-SMX, potentially exacerbating liver injury."
            },
            {
                "agent": "Lisinopril",
                "role": "UNLIKELY",
                "rationale": "Long-term use without prior hepatic events. Not typically associated with acute severe hepatocellular injury of this pattern."
            }
        ],
        "severityAssessment": {
            "overallSeverity": "SEVERE DILI / ACUTE LIVER FAILURE RISK",
            "features": [
                "Jaundice (Total Bilirubin 12.5 mg/dL)",
                "Hepatic Encephalopathy (Confusion, disorientation, asterixis, GCS 13)",
                "Marked transaminitis (ALT 1650 U/L, AST 2100 U/L)",
                "Elevated INR (though currently 1, can rapidly change)"
            ],
            "prognosisNote": "The patient presents with features concerning for acute liver failure. The presence of encephalopathy and high bilirubin levels indicates a high risk of severe outcomes. Prompt management, including drug withdrawal and supportive care, is critical."
        },
        "exclusionOfAlternativeCausesRequired": [
            "Viral hepatitis (HAV, HBV, HCV, HEV)",
            "Autoimmune hepatitis",
            "Alcohol-related liver disease",
            "Ischemic hepatitis",
            "Sepsis/multiorgan failure",
            "Metabolic or inherited disorders"
        ],
        "localGuidelinesComparison": {
            "status": "GAP IDENTIFIED",
            "details": "The provided local guidelines focus on specific conditions like Tacrolimus treatment, alcohol-related liver disease, and interventional procedures. They do not contain specific diagnostic criteria or frameworks for Drug-Induced Liver Injury (DILI). Therefore, EASL guidelines are the sole basis for DILI assessment in this case."
        },
        "references": [
            "EASL Clinical Practice Guidelines: Drug-induced liver injury - Introduction to DILI Classification",
            "EASL Clinical Practice Guidelines: Drug-induced liver injury - Patterns of DILI",
            "EASL Clinical Practice Guidelines: Drug-induced liver injury - Laboratory Workup for Excluding Alternative Causes"
        ]
    },
    "zone": "dili-analysis-zone"
}